Azintuxizumab vedotin

N/A

Report date: 2024/02/05 14:09:15

Base Information

Drug NameAzintuxizumab vedotin

Drug Alias NameABBV-838

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsAnti-SLAMF7

TargetsSLAM family member 7Tubulin

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaGermany +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbvie Inc

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A